Key Takeaways Neera Clase, who has served as interim CCO of Tarsus Pharmaceuticals since July, was appointed as the company’s ...

Glaukos and RevOpsis Therapeutics have entered into an exclusive license agreement to develop and commercialize RO-104, a tri-specific biologic for the treatment for retinal disease The agreement ...

The first patient has been dosed in Nacuity Pharmaceuticals’ global, confirmatory phase 3 clinical trial of NPI-001 tablets for the treatment of retinitis pigmentosa associated with Usher Syndrome.

The discovery could advance understanding of glaucoma, age-related macular degeneration, and other ocular diseases, although studies in humans are needed Researchers from the University of British ...

Lenz Therapeutics announced a major strategic reorganization and CEO transition designed to reduce operating expenses and prioritize consumer marketing for its presbyopia treatment. The reorganization ...

The acquisition adds Encelto, the first FDA-approved treatment for adults with idiopathic MacTel type 2, to Alcon’s retina portfolio Alcon announced its acquisition of Neurotech Pharmaceuticals for ...

SpyGlass Pharma announced positive 4-year first-in-human (FIH) trial results for the Bimatoprost Drug Pad-IOL (BIM-IOL) System in patients with mild-to-moderate open angle glaucoma or ocular ...

RxSight appointed Taryn Conway as chief commercial officer and Frank Shields as executive vice president of sales and commercial strategy The appointments support efforts to expand customer engagement ...

Siloton secured £8.4 million from Innovate UK to accelerate development of its handheld GiraffeOCT retinal imaging system Clinical trials with Sunderland Specialist Eye Hospital will evaluate the ...

LUCIA did not achieve the primary endpoint of statistical noninferiority in mean change in BCVA versus on-label aflibercept (Eylea, Regeneron) control, despite demonstrating visual improvement. Key ...

Significant benefits were reported in steroid-free quiescence, retinal vascular leakage, macular edema, and visual functioning No new safety signals were identified, and Priovant plans an FDA ...